Workflow
sublingual cladribine ODF
icon
Search documents
BioNxt Enters Commercialization Phase with Global Patent Protection and U.S. Fast Track Strategy for Sublingual Drug Delivery Platform
Accessnewswire· 2026-03-24 09:10
VANCOUVER, BC / ACCESS Newswire / March 24, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce a major advancement in its commercialization strategy, supported by a rapidly expanding global patent portfolio for its proprietary sublingual drug delivery platform. BioNxt has established a broad and defensible intellectual property position across key global markets, forming the ...